Test ID FCUIP CU (Chronic Urticaria) Index Panel
Specimen Required
Patient preparation: Patients taking calcineurin inhibitors should stop medication 72 hours prior to draw. Patients taking prednisone should be off their medication for 2 weeks prior to draw.
Specimen Type: Serum
Container/Tube: Red or SST
Specimen Volume: 3 mL
Collection Instructions: Draw blood in Red-top tube (SST is acceptable). Separate from cells within 2 hours of draw. Send 3 mL of serum refrigerate in a plastic vial.
Method Name
Immunoassay; Ex Vivo Challenge; Cell Culture and Histamine Analysis
Reporting Name
CU (Chronic Urticaria) Index PanelSpecimen Type
SerumSpecimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 7 days | |
Frozen | 7 days | ||
Ambient | 5 days |
Reference Values
Anti-Thyroid Peroxidase IgG:Â Â Â Â <35 IU/mL
Anti-Thyroglobulin IgG:Â Â Â Â Â Â Â Â Â Â Â Â <40 IU/mL
TSH (Thyrotropin):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0.4-4.0 uIU/mL
CU Index:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <10.0
The CU Index test is the second generation Functional Anti-FceR test. Patients with a CU Index greater than or equal to 10 have basophil reactive factors in their serum which supports and autoimmune basis for disease.
Day(s) Performed
Monday, Wednesday, Friday
Report Available
2 to 9 daysPerforming Laboratory
Eurofins ViracorTest Classification
This test was developed and its performance characteristics determined by Viracor Eurofins. It has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
84443
86343
86376
86800
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
FCUIP | CU (Chronic Urticaria) Index Panel | 69040-4 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
Z3144 | Anti-Thyroid Peroxidase IgG | 18332-7 |
Z3145 | Anti-Thyroglobulin IgG | 56635-6 |
Z3146 | TSH (Thyrotropin) | 3016-3 |
Z3147 | CU Index | 63369-3 |